research use only

Fezolinetant Neurokinin Receptor antagonist

Name: Fezolinetant
Brand: Selleck Chemicals
SKU: E0109
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E0109

Fezolinetant (ESN-364) is a potential antagonist of the neurokinin 3 receptor (NK3R). It interrupts pulsatile lh secretion and moderates levels of ovarian hormones throughout the menstrual cycle.

Fezolinetant Neurokinin Receptor antagonist Chemical Structure

Quality Control

Batch: E010901 DMSO]72 mg/mL]false]Ethanol]9 mg/mL]false]Water]Insoluble]false Purity: 99.64%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

99.64

Related Targets	CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas
Other Neurokinin Receptor Inhibitors	Tradipitant L-732138 Substance P Asparagus Extract Elinzanetant Maropitant citrate

Solubility

In vitro
Batch:

DMSO : 72 mg/mL (200.89 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 9 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.600mg/ml (10.04mM)	Taking the 1 mL working solution as an example, add 50 μL of 72 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.900mg/ml (2.51mM)	Taking the 1 mL working solution as an example, add 50 μL of 18 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	358.39	Formula	C₁₆H₁₅FN₆OS	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1629229-37-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	neurokinin 3 receptor
References	[1] https://pubmed.ncbi.nlm.nih.gov/34000049/ [2] https://pubmed.ncbi.nlm.nih.gov/26305889/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07606664	NOT_YET_RECRUITING	Menopause Hot Flashes	Rebecca Thurston	2026-09-25	PHASE3
NCT06975111	RECRUITING	Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular	University of Colorado, Denver	2026-03-01	PHASE2; PHASE3
NCT06957691	RECRUITING	Prostate Cancer; Prostate Cancer (Adenocarcinoma); Prostate Cancer Metastatic Disease; Prostate Cancer Recurrent; Prostate Carcinoma; Prostate Neoplasm; Prostate Adenocarcinoma; Prostate Cancer With Bone Metastasis; Vasomotor Disturbance; Vasomotor Symptoms; Vasomotor Symptoms (VMS); Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men; Vasomotor Symptoms; Hot Flashes; Androgen Deprivation Therapy; Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma; Androgen-deprivation Therapy; Hot Flashes; Hot Flushes; Hot Flushes and/or Sweats	Shehzad Basaria, M.D.	2026-01-14	PHASE2
NCT06917313	RECRUITING	Breast Cancer Early Stage Breast Cancer (Stage 1-3)	Yale University	2025-12-05	PHASE2
NCT07568236	NOT_YET_RECRUITING	Vasomotor Symptoms; Prostate Cancer	Chinese University of Hong Kong	2026-07-01	PHASE2
NCT07783282	NOT_YET_RECRUITING	Prostate Cancer	Astellas Pharma Global Development, Inc.	2026-08-31	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):